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CFTR mutations testing was performed on 980 CF suspected persons and their rel-
atives since early 1990s. The diagnosis of CF was established in 124 patients basing
on family history, typical clinical symptoms, elevated sweat chloride concentration
and DNA analysis data.
Based on the frequency and spectrum of the most common CFTR mutations in
Western Ukraine, we developed a protocol for practical CF diagnostic purposes.
Using this protocol we have the capability of detecting above 63.71% of CFTR
gene mutation alleles; 36.29% are not identiﬁable.
DNA samples were re-tested using the kit method (TM Bioscience, USA): 9
additional alleles were identiﬁed which together accounted 3.63%.
In the study group the following percent of mutant CF alleles was estab-
lished: F508del – 54.50, N1303K – 4.05, G542X – 3.15, CFTRdele2,3 – 3.15,
W1282X – 2.70, 3849+10kbC/T – 1.21. Mutations 1898-1G>A, 3272-1A>G,
R334W, 1717-1G>A, R553X, 2183AA>G, 621+1G>A, 2721del11, R347H were
encountered at a frequency less than 1%.
An important fact to consider is that in the North American Caucasian population
88.75% of CF mutations are identiﬁed with this method. In comparison, 31.45% of
CF alleles are unidentiﬁed in the Ukrainian population using this method. This per-
centage would be even higher (34.68%) if testing for mutation CFTRdele2,3(21kb)
were excluded.
The majority of patients have one identiﬁed F508del mutation with the other
unidentiﬁed allele. Our results conﬁrm the necessity of performing additional
analysis of DNA samples with unidentiﬁed CF alleles in order to establish other
speciﬁc mutations, which, similar to CFTRdele2,3(21kb), are widely distributed in
CF patients of Slavic origin but are not found in other populations.
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Genetic diagnosis is now available in Romania. Starting 2004 we use standard
Elucigene CF 29 kit, who identify the most frequent 29 European mutations
(1717−1G>A, G542X, W1282X, N1303K, DF508, 3849+10kbC>T, 621+1G>T,
R553X, G551D, R117H, R1162X, R334W, A455E, 2183AA>G, 3659delC,
1078delT, DI507, R347P, S1251N, E60X, D1152H, 3120+1G>A, 2789+5G>A,
1898+1G>A, 711+1G>T, G85E, 2184delA, I148T, R560T). Aim study: evaluation
of kit’s efﬁcacy in relation with mutations identiﬁed in Romania.
We evaluated 40 CF patients (pts) with typical forms, pozitive sweat test and at list
one identiﬁed allela.
Results: Mutation were, in order of frequency: DF508, G542X, N1303K, 621 + 1
G>T, I148T; their cumulative percentage corresponded to 17.2% from Elucigene
kit’s mutations. Genotypes found: 21 patients DF508 homozygous, 10 pts DF508/x
compound genotype, 5 pts DF508/G542X genotype, 1 DF508/N1303K, and 3 pts
with compound genotype: non-DF508 (I148T, N1303K, G542X)/x. Parent’s genetic
tests excluded the possibility of homozygous genotype for this alleles. Thus in 13
pts (32.5%) we could not identify the completed genotype.
Conclusions: Concordance of kits mutation with identiﬁed mutation in CF Roma-
nian patients is very low. Use of Elucigene CF 29 kit in Romania is limited, probably
because of important genetic heterogeneity, and limits signiﬁcantly heterozygous
diagnosis. Development of complementary or wide kits, besides the existing ones
is in discussion.
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The detection of mutation F508del in the CFTR gene was the ﬁrst DNA analysis
that started our activity in DNA diagnostics in 1992 (we made 25 DNA analysis
of F508del in CFTR gene). In 2007 we undertook the DNA analysis of CFTR
gene in 900 patients. To date we have been using a wide spectrum of methodical
assays and implemented the “cascade” strategy of routine molecular genetic testing
encompassing mutation and linkage analysis. A test based on melting point analysis
on a real-time PCR enable us to perform 7 major CF mutations in less than 1
hour. This test thus results in a sensitivity of about 85%. We detect the next 29
frequent mutations worldwide using INNO-LIPA CFTR strips. We use screening
methods DGGE and SSCP with consequent sequencing and recently HRM analysis
for screening of entire CFTR coding region to detect rare and unknown CFTR
sequence variants. Finally, in order to conﬁrm aberrant splicing we have prepared
the strategy to characterised aberrant CFTR transcript using expression analysis.
When making the analysis of CFTR gene, we collaborate especially with centres for
CF, centres for assisted reproduction, neonatologists, paediatricians, gynaecologists,
gastroenterologists etc. An integral part of DNA analysis of CFTR gene is the
genetic counselling.
In the near future we will participate in the neonatal screening for CF in CR. We
present a number of performed analyses of CFTR gene, methods we have used in
the CF diagnostics, indications for CFTR analysis, geographical distribution of CF
alleles in South Moravia. Our work is documented on some case reports.
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The incidence of CF is signiﬁcantly variable in Brazil, with differences larger than
20 fold, according with the ethnic group and geographic studied region. Portuguese
started colonization in the 16th century. The Netherlander invaded the northeast
in 1630. Africans were brought to Brazil, in a continuous forced migration, which
lasted from 16th to 19th centuries. In the 19th century, new migratory movements
have begun from Germany, Italy, Arab and Spain. In the ﬁrst three decades of the
20th century, started a new migratory ﬂow, mainly from Italy, Spain and Portugal.
After the World War II, Brazil received additional immigrants (Japanese, Jewish)
compounding its population.
This study generated the ﬁrst data about the CF incidence on the Brazilian Northeast
and also was obtained new data about the Southeast region.
At the time of this study, 70 non related patients were attended at the local CF center
with 2 positive sweat tests in Campinas-SP city. On these patients were screened
the following mutations: DF508 (50%), G542X (4.29%), R1162X (2.14%), N1303K
(1.43%) and R553X (0.71%). The mutation G551D wasn’t found.
The DF508 mutation was also analyzed in 1,138 healthy voluntary women, 694
from Campinas – SP and 444 from Joa˜o Pessoa – PB, with average age of 26.3
years (15−39), ±6.8. In the samples collected in Campinas – SP n = 694 wasn’t
found any mutated allele 0/1,388 and so, we weren’t able to make any incidence
calculation through this method.
In the 888 alleles from Joa˜o Pessoa, 4 carry the DF508 mutation (p = 0.0045).
Knowing that this mutation accounts for approximately 50% of the FC patients
alleles in Brazil, the incidence of the CF in this region was estimated using the
proportion: (0.0045/0.5) = 0.009. Thus, the estimated incidence of this recessive
disease in Joa˜o Pessoa was 1:12,321.
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